UnknownNot Applicable

Platelet Transfusion in Acute Intracerebral Hemorrhage

Finland100 participantsStarted 2009-01

Plain-language summary

* To prove whether use of antiplatelet agents results into a rapid enlargement of hematoma after onset of acute intracerebral hemorrhage. * To prove the efficacy and safety of platelet transfusion for prevention of hematoma growth in patients who were stricken by acute intracerebral hemorrhage while being on antiplatelet medication.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * being on either aspirin or clopidogrel or a combination of aspirin and dipyridamole * acute primary ICH * \> 17 years * admitted within 6 h after onset of ICH * ICH score \< 4 Exclusion Criteria: * other type of ICH than acute primary intracerebral hemorrhage * patients who need neurosurgery * life expectancy less than 3 months due to comorbid disorders * confirmed malignant disease (cancer) * confirmed acute myocardial infarction * hepatitis and/liver cirrhosis * renal failure * infectious disease (HIV, endocarditis etc.) * current or previous hematologic disease * women of childbearing age if pregnant * participation in another study within the preceding 30 days

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Hematoma growth within 24 h measured as increase in hematoma volume observed by head CT

Timeframe: 24 hours

Trial details

NCT IDNCT00699621

SponsorUniversity of Oulu

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-07

Contact for this trial

Matti E Hillbom, MD, PhD

358-8-315-4518 matti.hillbom@oulu.fi

View on ClinicalTrials.gov More Intracerebral Hemorrhage trials